Skip to content
value.today
Akari Therapeutics, PLC logo

Akari Therapeutics, PLC

AKTX
$13 Mmarket cap on Aug 1, 2026-7.1% since Jan 2024
Compare
World rank
#25,367
Revenue
—
For year ending December-2025
Net income
$-17 M
SEC filing
Employees
6
As of March 1, 2026
SEC filing

Akari Therapeutics, PLC in brief

Akari Therapeutics, PLC is a listed company in the Biotechnology industry, based in Tampa, Florida, USA. Its market value was $13 M on 1 August 2026, which makes it the 25,367th largest listed company in the world and the 4,238th largest in the USA on this site. It employs about 6 people and Abizer Gaslightwala is its chief executive. Its shares trade under the symbol AKTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Akari Therapeutics, PLC

We are an oncology company developing next-generation antibody-drug conjugates built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. PH1’s disruption of normal RNA splicing has multiple modes of action on cancer cells: 1) cell killing and cytotoxicity that causes cancer cell death and 2) generates neoantigen proteins that activates both the innate and adaptive immune systems to drive robust and durable cancer killing activity in preclinical models. Additionally, AKTX-101 is active against urothelial cancers with FGFR3- fusions, lung cancers with SMARCA4 deletions and BRAF G466V mutations, and K-Ras G12V driven pancreatic cancers, whereas the PH1 payload has been demonstrated to be active against metastatic prostate cancer cells driven by AR-v7 and AR-hormone dependent prostate cancer showing the power of the PH1 payload against oncogenes derived from spliced isoforms/variants. Utilizing the novel PH1 payload as a platform, the Company has the ability to generate a pipeline of ADC candidates each focused on a different cancer antigen target of interest (i.e. Trop-2, CEACAM5). Akari’s lead candidate, AKTX-101, targets the Trop-2 receptor on cancer cells and is engineered with a proprietary linker to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative in animal models relative to an ADC with a traditional payload (topoisomerase1 inhibitor).

From the company's annual report filed with the US SEC: read the report

Akari Therapeutics, PLC timeline

4 events, 2012–2015
  1. 2012
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2013
  4. ✎
    Renamed Celsus Therapeutics Plc.
    Formerly Morria Biopharmaceuticals PLC.
  5. 2014
  6. 🔔
    Initial public offering as Celsus Therapeutics Plc.
    Final prospectus filed with the SEC on 31 January 2014; shares registered for exchange trading on 30 January 2014.
  7. 2015
  8. ✎
    Renamed Akari Therapeutics Plc
    Formerly Celsus Therapeutics Plc..

Events of Akari Therapeutics, PLC from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$19 M$38 M$58 M$77 M2020202120222023202420252026

World rank over time

▲ up 388 places since 2020
2020-01-01: #23009#23,00920202021-01-01: #19443#19,44320212022-01-07: #25052#25,05220222022-12-25: #28176#28,17620222023-07-30: #28998#28,99820232024-01-05: #30086#30,08620242026-03-08: #12605#12,60520262026-08-01: #22621#22,6212026

Rank in USA: #4,257 (Jan 2020) · #3,880 (Jan 2021) · #4,702 (Jan 2022) · #5,138 (Dec 2022) · #5,150 (Jul 2023) · #4,446 (Jan 2024) · #2,360 (Mar 2026) · #4,010 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.5×
Free cash flow yield
-126.4%
Net margin
—
Operating margin
—
Return on equity
-61.1%
Liabilities / assets
40.8%
Revenue growth
-39.3%
R&D / revenue
1473.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-21M—FY18Fiscal year ending Dec 2019: revenue —, net income $-17M—FY19Fiscal year ending Dec 2020: revenue —, net income $-17M—FY20Fiscal year ending Dec 2021: revenue —, net income $-17M—FY21Fiscal year ending Dec 2022: revenue $1M, net income $-13M$1MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-10M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-20M—FY24Fiscal year ending Dec 2025: revenue —, net income $-17M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-17M$-17M—
Dec 2024——$-22M$-20M—
Dec 2023$0M-39.3%$-17M$-10M-2705.4%
Dec 2022$1M—$-12M$-13M-2145.9%
Dec 2021——$-17M$-17M—
Dec 2020——$-18M$-17M—
Dec 2019——$-17M$-17M—
Dec 2018——$-21M$-21M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M——$0.00—
Dec 2024$-13M——$0.00—
Dec 2023$-16M$0M$-16M$0.00—
Dec 2022$-7M$0M$-8M$-0.74—
Dec 2021$-19M——$0.00—
Dec 2020$-17M——$-0.01—
Dec 2019$-13M$0M$-13M$-0.01—
Dec 2018$-23M$0M$-23M$-0.01—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-6M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-14M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-5M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Akari Therapeutics, PLC with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-17 M
Net income
$-17 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$48 M
Total liabilities
$20 M
Total equity
$28 M

As of December-2025

Top 13 institutional investors in Akari Therapeutics, PLC#

As of Sep 30, 2026
13 institutions held 135,775 shares (about 8.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 8.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 13 largest institutional investors in Akari Therapeutics, PLC
#InstitutionShares heldChange (shares)% heldValueFiled
1Vestmark Advisory Solutions, Inc.37,688New2.28%$0 MNov 16, 2026
2Jane Street Group, LLC23,242+7,779 (+50.31%)1.41%$0 MNov 12, 2026
3Citadel Advisors LLC21,637New1.31%$0 MNov 16, 2026
4Cresset Asset Management, LLC20,5610 (0.00%)1.24%$0 MNov 16, 2026
5Occidental Asset Management, LLC18,125New1.10%$0 MNov 5, 2026
6MMCAP International Inc. SPC11,427-88,573 (-88.57%)0.69%$0 MNov 12, 2026
7GAMMA Investing LLC2,411New0.15%$0 MOct 8, 2026
8Tower Research Capital LLC (TRC)385New0.02%$0 MNov 16, 2026
9IFP Advisors, Inc1810 (0.00%)0.01%$0 MOct 16, 2026
10Nuveen, LLC86New0.01%$0 MNov 10, 2026
11SBI Securities Co., Ltd.15+1 (+7.14%)0.00%$0 MOct 22, 2026
12Caitong International Asset Management Co., Ltd10+2 (+25.00%)0.00%$0 MOct 29, 2026
13Northwestern Mutual Wealth Management Co70 (0.00%)0.00%$0 MNov 13, 2026

Insider trading at Akari Therapeutics, PLC#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
15
since
$37 K$0Jun 2025: bought $37 K (4 trades), sold $0 (0 trades)Jun 25Aug 2025: bought $20 K (3 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Akari Therapeutics, PLC: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Abizer GaslightwalaCEO, DirectorOption exercise+19,333$0.000$833,440Form 4
filed Abizer GaslightwalaCEO, DirectorOption exercise+7,733$0.000$341,173Form 4
filed Robert B. BazemoreDirectorOption exercise+773$0.000$019,666Form 4
filed Sandip I. PatelDirectorOption exercise+3,866$0.000$232,691Form 4
filed Robert B. BazemoreDirectorOption exercise+3,093$0.000$122,759Form 4
filed Sandip I. PatelDirectorOption exercise+6,186$0.000$238,877Form 4
filed Samir Rashmikant PatelDirectorGrant or award+2,236$7.899$18 K12,102Form 4
filed Robert B. BazemoreDirectorGrant or award+4,677$7.899$37 K18,893Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Akari Therapeutics, PLC#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
17,903
0.0% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-11-18 15:42 UTC, code LUDP, resumed 15:52 UTC
  • 2026-11-18 15:18 UTC, code LUDP, resumed 15:29 UTC
  • 2026-05-28 13:55 UTC, code LUDP, resumed 14:05 UTC
  • 2026-05-26 15:17 UTC, code LUDP, resumed 15:22 UTC
  • 2026-05-26 14:00 UTC, code LUDP, resumed 14:05 UTC

Fails to deliver

  • : 3,419 shares at $8.53
  • : 3,238 shares at $9.20
  • : 2,931 shares at $8.58
  • : 24 shares at $8.23
  • : 1,624 shares at $8.76

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Akari Therapeutics, PLC scorecard#

Passes 0 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year0.00 vs 0.00Diluted EPS 0.00 in fiscal 2025 against 0.00 the year before (report's currency).
    • ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$17 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-68.4%-68.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.44 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-172.8×Operating income -172.8 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year181.8%Diluted shares up 181.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Akari Therapeutics, PLC: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Akari Therapeutics, PLC: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development2.87.05.59.6r9.18.88.7122317
Selling, general and administrative9.39.71114r8.19.28.212r129.9
Operating expenses1722172317181721r3827
Operating income−17−22−17−23r−17−18−17−21r−38−27
Interest and finance income0.00.00.10.0r0.00.00.00.20.20.1
Interest expense and finance costs0.10.2——————00
Other non-operating income (expense)−1.01.96.8r5.3−0.20.90.1r0.3r2.49.1
Income before tax−18−20−10r−0.0r−17−17−17r−20r−35−18
Income tax−1.0000000000
Net income attributable to shareholders−17−20−10−18r−17−17−17r−20r−35−18
Earnings per share, basic0.000.000.000.000.00-0.01-0.01-0.01-0.03-0.02
Earnings per share, diluted0.000.000.000.000.00-0.01-0.01-0.01-0.03-0.02
Shares, weighted average (basic)67,32823,8889,7896,2434,2923,1591,8311,5401,2471,178
Shares, weighted average (diluted)67,32823,8889,7896,2434,2923,1591,8311,5401,2471,178
Balance sheet
Cash and cash equivalents5.2r0r3.813r9.4145.75.42834
Short-term investments————————010
Other current assets0.00.20.20.1r0.10.2r0.71.40.71.5
Current assets5.53.04.314r12156.4r7.52946
Property, plant and equipment———0000.00.00.10.1
Goodwill8.48.4————————
Other intangible assets——0.00.0r0.00.00.00.00.00.0
Total assets48514.414r12156.5r8.02946
Accounts payable8.8121.70.9r1.83.41.21.62.02.2
Current liabilities12204.6————4.91212
Non-current liabilities———————00.00.1
Total liabilities20284.612r6.15.26.5r4.91212
Retained earnings−265−247−227−217r−200−182−165r−127−110−75
Shareholders' equity2822−0.21.8r5.6r9.40.0r4.4r22r34
Total liabilities and equity48514.414r12156.5r8.02946
Shares outstanding90,53753,18713,2347,4454,760r3,8472,2460.3r1,5261,178
Cash-flow statement
Depreciation and amortization—0.00.00.0r0.00.00.00.00.00.0
Share-based compensation2.92.21.20.7r0.30.31.01.62.73.9
Cash from operating activities−11−13−16−22r−19−17−13−23r−32−25
Capital expenditure——————00−0.0−0.1
Cash from investing activities—0.4————0010.0−10
Debt repaid−0.6−0.8————————
Shares issued11127.025r1425130.5r16r0
Cash from financing activities13117.025r1425130.5r160
Exchange-rate effect on cash0.0−0.00.00.1r−0.10.20.0−0.0−0.1−0.1
Change in cash2.6−1.2−9.43.9r−4.78.3−0.2−22−6.0r−35r
Report10-K10-K10-K10-K20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Akari Therapeutics, PLC operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.

Akari Therapeutics, PLC: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office3 subsidiaries—
🇮🇱 Israel1 subsidiary—
🇲🇹 Malta1 subsidiary—
🇨🇭 Switzerland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Akari Therapeutics, PLC#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 4 · Material agreement 7 · Agreement ended 2 · New debt 1 · Unregistered share sale 4 · Shareholder rights changed 1 · Shareholder vote 5 · Results announced 3

Akari Therapeutics, PLC: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder rights changed8-K
Shareholder vote8-K
Material agreementAgreement endedUnregistered share sale8-K
Shareholder vote8-K
Delisting notice8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Material agreementAgreement endedNew debt8-K
Directors and officersShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 acquisitions

Businesses it acquired

Acquisitions by Akari Therapeutics, PLC
AcquiredAcquisition dateCompletionPriceStakeSource
Peak BioNov 2024Nov 2024——Annual report

Private share sales · funding history

Private share sales of Akari Therapeutics, PLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$13 MPrivate placement after listing$10 to $50 million21optionsSEC
Jul 2021$12 MPrivate placement after listing$10 to $50 million62equity, optionsSEC
Feb 2020$10 MPrivate placement after listing$2 to $10 million53equity, optionsSEC
Jun 2019$5 MPrivate placement after listing$2 to $10 million45optionsSEC
Sep 2015$75 MPrivate placement after listing$50 to $250 million28equitySEC
Sep 2013$13 MPrivate placement after listing$10 to $50 million18equitySEC
Nov 2012$2 MPrivate placement after listingUnder $2 million20equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Akari Therapeutics, PLC#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-05-01
Akari Therapeutics, PLC: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
Akari Therapeutics, PLC: latest layoffs
AnnouncedPeopleKindWhereSource
67% of workforceRestructuring planSEC 8-K“On May 1, 2024, Akari Therapeutics, Plc (the “Company”) began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced pr…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Akari Therapeutics, PLC compares in Biotechnology

  • Market cap$13 M · higher than 13% of 726
  • Revenue growth-39.3% · higher than 24% of 438
  • Price / book0.5× · lower than 93% of 534
  • FCF yield-126.4% · higher than 7% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Akari Therapeutics, PLC🇺🇸$13 M——-39.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Akari Therapeutics, PLC? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Akari Therapeutics, PLC's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Akari Therapeutics, PLC? Suggest a correction